T
Torque Therapeutics
Immunotherapies to address cancers focused on the specific modulation of immune cell subsets
About Torque Therapeutics
Torque Therapeutics operates in the biotechnology sector, focusing on developing innovative therapies by decoding the molecular codes used by T cells to prevent and cure diseases. The company serves patients in need of advanced medical treatments, particularly those with conditions that have been resistant to traditional therapies. Torque Therapeutics utilizes a unique approach by learning from the immune responses of individuals who have successfully fought off diseases. This information is then used to design and deliver multiclone therapies, which are tailored to target specific molecular codes within the immune system. The business model revolves around extensive research and development, clinical trials, and eventual commercialization of these therapies. Revenue is generated through partnerships, licensing agreements, and sales of proprietary treatments.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 78
- Open positions
- None listed
- Dealroom signal
- 73.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Mar 2020
- Capital deployed
- —
- Preferred round
- MERGER
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Torque Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Mar 2020 | $0 | — | Repertoire Immune Medicines · Cogen Immune Medicines | ↗ |
| SERIES A✓Equity / VC | Nov 2017 | $25M | $100M | Flagship Pioneering | — |
Growth signals
Latest recorded traffic for Torque Therapeutics is 680 monthly website visits, up 94.3% over the last three months. Torque Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors4 additional known investors
Repertoire Immune Medicines- CMCogen Immune Medicines
Massachusetts Institute of Technology
Technical University of Denmark
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Torque Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Torque Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.